TY - JOUR
T1 - Mucosal irritant potential of a potassium-sparing diuretic and of wax-matrix potassium chloride
AU - Ryan, Jerome R.
AU - McMahon, F. Gilbert
AU - Akdamar, Kemal
AU - Ertan, Atilla
AU - Agrawal, Naurang
PY - 1984/1/1
Y1 - 1984/1/1
N2 - To measure their relative upper gastrointestinal irritant potential, either 5 mg amiloride and 50 mg hydrochlorothiazide (twice dailv) or 24 mEq wax--matrix potassium chloride (three times a day) were given to 30 normal subjects with no prior endoscopic abnormalities in the esophagus, stomach, or duodenum. All subjects received glycopyrrolate, 2 mg (3 times a day) to slow gastric emptying. Repeat endoscopy after 7 days of treatment with war-matrix potassium chloride revealed that 10 of 15 (67%) of the subjects developed one or more gradable upper gastrointestinal lesions (esophageal ulcer, gastric ulcer, eight cases of one or more mucosal erosions, and, four cases of hyperemia or edema of the esophagus, stomach, or duodenum). Four subjects (27%) taking amiloride/hydrochlorothiazide developed either mild hyperemia or edema, but there were no erosions or ulcers in this group.
AB - To measure their relative upper gastrointestinal irritant potential, either 5 mg amiloride and 50 mg hydrochlorothiazide (twice dailv) or 24 mEq wax--matrix potassium chloride (three times a day) were given to 30 normal subjects with no prior endoscopic abnormalities in the esophagus, stomach, or duodenum. All subjects received glycopyrrolate, 2 mg (3 times a day) to slow gastric emptying. Repeat endoscopy after 7 days of treatment with war-matrix potassium chloride revealed that 10 of 15 (67%) of the subjects developed one or more gradable upper gastrointestinal lesions (esophageal ulcer, gastric ulcer, eight cases of one or more mucosal erosions, and, four cases of hyperemia or edema of the esophagus, stomach, or duodenum). Four subjects (27%) taking amiloride/hydrochlorothiazide developed either mild hyperemia or edema, but there were no erosions or ulcers in this group.
UR - http://www.scopus.com/inward/record.url?scp=0021327138&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021327138&partnerID=8YFLogxK
U2 - 10.1038/clpt.1984.13
DO - 10.1038/clpt.1984.13
M3 - Article
C2 - 6690174
AN - SCOPUS:0021327138
VL - 35
SP - 90
EP - 93
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
SN - 0009-9236
IS - 1
ER -